PF-06256142 is a potent, selective, CNS-penetrant and orally active agonist of the D1 receptor , with an EC 50 and K i of 33 nM and 12 nM, respectively. PF-06256142 has the potential for the research of schizophrenia and Parkinson's disease In Vitro PF-06256142 exhibits IC 50 values of 10 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PF-06256142 exhibits high oral bioavailability (rat 85%) following oral administration (rat 5 mg/kg) . PF-06256142 exhibits terminal elimination half-life (rat 2.3 h) following intravenous administration (rat 5.0 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat Dosage: 5.0 mg/kg for i.v.; 5 mg/kg for oral (Pharmacokinetic Analysis) Administration: Intravenous injection and oral administration Result: Oral bioavailability (85%), T 1/2 (2.3 h). Form:Solid IC50& Target:Human D 1 Receptor 33 nM (EC 50 )